All studies
AuthorisedTherapeutic exploratory (Phase II)Interventional

Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial.

Dense breast tissue contains more glandular and fibrous tissue than fatty tissue. While having dense breasts is common, it can make it harder for doctors to spot early changes on a mammogram and is linked to a higher risk of developing breast cancer. This early-stage study is testing two different daily tablets, called linzagolix and bilastine, in women who have not yet reached the menopause and are at higher risk of breast cancer. Researchers want to find out if taking one of these medicines for one year can safely reduce breast density. Throughout the study, doctors will monitor participants using mammograms, bone scans, blood tests, and surveys about wellbeing. The aim is to see if these treatments could become a new, safe way to help lower breast cancer risk in the future.

At a glance

Status
Authorised
Phase
Therapeutic exploratory (Phase II)
Sponsor
Consorci Mar Parc De Salut De Barcelona
Enrolment target
150
Start
01 Oct 2026

What is this study about?

Breasts are made up of fatty tissue and dense tissue. Dense tissue includes the glands that produce milk and the supportive tissue around them. Having dense breasts is very common and completely normal. However, dense tissue shows up white on a mammogram, which can make early signs of cancer harder to see. It is also linked to a higher risk of developing breast cancer in the future.

Doctors are looking for new ways to lower this risk, particularly for women who are already at a higher chance of developing breast cancer before menopause. This clinical trial is testing two different medicines: linzagolix (a tablet normally used to treat womb conditions) and bilastine (an antihistamine tablet). Researchers believe these medicines might help reduce the amount of dense tissue in the breasts.

During the trial, women will take their assigned tablet daily for 12 months. Special computer software will check their mammograms at the start and end of the year to measure any changes in breast density. Doctors will also check bone health, general wellbeing, and any side effects to see if the treatments are safe and manageable.

Key takeaways

  • Tests whether linzagolix or bilastine can reduce breast density over 12 months.
  • Aimed at premenopausal women aged 18 and over who have a higher risk of breast cancer.
  • Involves taking daily tablets and attending regular hospital visits for mammograms and health checks.
  • Monitors bone health, mood, quality of life, and safety throughout the year.
  • Taking part is completely voluntary, and you can stop at any time.

Who may be eligible?

This study is open to adult women aged 18 and older who have not yet reached the menopause (premenopausal). Participants must have a higher-than-average risk of developing breast cancer, which may be due to a strong family history, genetic factors, or previous breast health checks.

Because the study focuses on premenopausal women, you will not be able to join if you have already gone through the menopause. Doctors will also check that you are in suitable general health and are able to attend regular hospital appointments for check-ups and scans.

A full set of medical checks will be done by the study team to confirm your breast density and check whether the trial medicines are safe for you to take.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am a woman aged 18 or older.
  2. I have not yet gone through the menopause.
  3. I have been told I am at higher risk of breast cancer.
  4. I am willing to take a daily tablet for 12 months.
  5. I am able to attend regular hospital appointments for scans and blood tests.
Answer every question to see your result.

What does participation involve?

Taking part in this study lasts for about 12 months. You will be asked to take study tablets (either linzagolix or bilastine) once daily as directed by the medical team.

You will need to visit the clinic for several appointments over the year. During these visits, you will have mammograms to measure your breast density, bone density scans (DXA scans) to make sure your bones remain strong, and regular blood tests. You will also complete short questionnaires about your mood, quality of life, and how easy you find taking the medicine. The research team will track any symptoms or side effects you experience throughout the year.

Potential risks and benefits

Taking part may help lower your breast density, which could make future mammograms clearer, and your participation will help doctors learn more about preventing breast cancer. However, there is no guarantee you will personally benefit. Both medicines can cause side effects, and hormone-blocking medicines like linzagolix can sometimes cause hot flushes or temporarily affect bone strength. You will be closely monitored with regular scans and safety checks. Joining is entirely your choice, and you are free to leave the trial at any time without it affecting your usual NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Spain

Common questions

What does having dense breasts mean?

Dense breasts have more supportive and glandular tissue than fat. It is very common, but it can make mammograms harder to read and slightly increases breast cancer risk.

Will taking these tablets protect me from breast cancer?

We do not know yet. This study is testing whether the tablets lower breast density, which doctors hope might help reduce risk in the future.

What happens if I get unpleasant side effects?

You should tell the study team straight away. They can offer advice, change your care, or help you safely stop taking the tablets if needed.

Do I have to pay to take part?

No, clinical trial medicines and study-related tests are provided free of charge, and travel expenses are often covered.

Can I leave the study if I change my mind?

Yes, you can leave the study at any point without giving a reason, and your regular medical care will continue as normal.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.